Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200430 | 0.89 | MAPT (0.49) | PDE4DPDE4BALDH1A1NPSR1ELANE | |
| SCHEMBL2198847 | 0.88 | NOTUM (0.47) | SCN9ANPSR1NOTUMPOLBNPY5R | |
| SCHEMBL2199422 | 0.88 | SCN9A (0.45) | PDE4DPDE4BSCN9AALDH1A1NPSR1 | |
| SCHEMBL2199384 | 0.86 | PDE4D (0.67) | PDE4DPDE4BALDH1A1NPSR1SLC34A1 | |
| SCHEMBL2200842 | 0.86 | NPSR1 (0.43) | SCN9AALDH1A1NPSR1NOTUMELANE | |
| SCHEMBL2201758 | 0.85 | SCN9A (0.42) | PDE4DPDE4BSCN9AALDH1A1NPSR1 | |
| SCHEMBL2199120 | 0.85 | NPY5R (0.41) | PDE4DPDE4BSCN9AALDH1A1NPSR1 | |
| SCHEMBL2200720 | 0.84 | ALDH1A1 (0.49) | PDE4DPDE4BSCN9AALDH1A1NPSR1 | |
| SCHEMBL2200564 | 0.83 | SCN9A (0.44) | PDE4DPDE4BSCN9AALDH1A1NPSR1 | |
| SCHEMBL2202684 | 0.81 | KMT2A (0.44) | SCN9ANOTUMNPY5RSLC5A1SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | PDE4D 814/4885PDE4B 607/4885SCN9A 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.